<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537533</url>
  </required_header>
  <id_info>
    <org_study_id>BRC</org_study_id>
    <nct_id>NCT04537533</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Infusion in Low Dose Versus in High Dose for Reducing Blood Loss in Radical Cystectomy Operations</brief_title>
  <official_title>Intraoperative Tranexamic Acid Infusion in Low Dose Versus in High Dose for Reducing Blood Loss and Its Effect on Postoperative Thromboembolic Complications in Radical Cystectomy Operations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer is one of the most common cancers of the genitourinary tract in adults, and&#xD;
      its incidence distinctly increases with age . In almost two-thirds of cases, the disease is&#xD;
      superficial at presentation and involves the mucosal and sub mucosal layers or the lamina&#xD;
      propria of the bladder, whereas ∼20% to 30% of patients have muscle-invasive tumors.&#xD;
      Superficial bladder cancer is treated by transurethral endoscopic resection, which can be&#xD;
      followed by endovesical therapy for patients at risk of disease recurrence and progression .&#xD;
      In contrast, muscle-invasive bladder cancer is generally treated by radical cystectomy with&#xD;
      pelvic lymph node dissection and then creation of urinary diversion to create an alternate&#xD;
      route for urine passage, which demonstrates 10-year recurrence-free survival rates of 50% to&#xD;
      59% and overall survival rates of ∼45% .&#xD;
&#xD;
      These major surgeries have a prolonged operative times and are associated with significant&#xD;
      risk of complications including high risk of perioperative bleeding and subsequent need for&#xD;
      blood transfusion with significant postoperative complications, which are reportedly in the&#xD;
      range of 24% to 64% .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among individual surgeons at institutions that perform many procedures, median intraoperative&#xD;
      blood loss is between 600 and 1700 mL. The incidence of at least one intraoperative blood&#xD;
      transfusion is 9 to 67%, and the postoperative transfusion risk is at least 15%. Among&#xD;
      cystectomy patients who receive transfusion, a median of 2 units of blood cells are given.&#xD;
      Therefore, it is very important to establish surgical and anesthetic protocols aimed at&#xD;
      minimizing intraoperative blood loss and subsequent blood transfusion requirements in order&#xD;
      to improve postoperative outcomes.&#xD;
&#xD;
      Venous thromboembolism (VTE) in radical cystectomy can account for up to 22% of total deaths&#xD;
      after surgery . In the bladder cancer literature, symptomatic thromboembolic events occur in&#xD;
      up to 8.3% of patients , but subclinical deep vein thrombosis (DVT) rates can be as high as&#xD;
      24.4% when examining an ultrasonography (US)-screened population . In fact, undergoing a RC&#xD;
      is a significant, independent risk factor on multivariable analysis for developing a deep&#xD;
      venous thrombosis.&#xD;
&#xD;
      Lysine analog drugs are synthetic derivatives of the amino acid lysine that reversibly block&#xD;
      lysine-binding sites on plasminogen molecules. This action prevents the conversion of&#xD;
      plasminogen to plasmin, the active enzyme that degrades fibrin clots. Therefore, lysine&#xD;
      analogs decrease the breakdown of clots and are considered anti-fibrinolytics. There are two&#xD;
      commonly studied lysine analogs, tranexamic acid and epsilon-aminocaproic acid. Both of these&#xD;
      drugs have been shown to decrease blood loss and blood transfusion need during some surgeries&#xD;
      without a significant increase in adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of low dose and high dose tranexemic acid infusion on Intraoperative blood loss .</measure>
    <time_frame>within the first 15 days</time_frame>
    <description>Estimated Blood Loss and perioperative need for blood transfusion within the first 15 days .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative thromboembolic events</measure>
    <time_frame>within the first 15 days</time_frame>
    <description>Post operative complications as deep venous thrombosis, pulmonary embolism, MI, cerebral stroke, blurred vision and seizures within the first 15 days .</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>first group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st group (A) will include 30 patients: each one will receive 15mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 10mg/kg/hour of I.V tranexemic acid as infusion all through the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>second group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2nd group (B) will include 30 patients: : each one will receive 5mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 1mg/kg/hour of I.V tranexemic acid as infusion all through the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3rd group (C){controlled group} will include 30 patients: each one will receive saline (placebo) injection and infusion all through the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Intraoperative infusion</description>
    <arm_group_label>first group</arm_group_label>
    <arm_group_label>second group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Third group</arm_group_label>
    <arm_group_label>first group</arm_group_label>
    <arm_group_label>second group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 - 70 years old&#xD;
&#xD;
          -  Gender: Males and females&#xD;
&#xD;
          -  ASA grade I - II&#xD;
&#xD;
          -  Patients undergoing radical cystectomy for bladder cancer regardless of tumor stage&#xD;
             and histology.&#xD;
&#xD;
          -  Patients who have undergone previous surgery, radiation, or chemotherapy may be&#xD;
             included.&#xD;
&#xD;
          -  All forms of urinary diversion are allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal.&#xD;
&#xD;
          -  Patient with allergy to tranexamic acid.&#xD;
&#xD;
          -  Patients have thromboembolic disease (active or diagnosed within 1 year), such as deep&#xD;
             vein thrombosis (DVT), pulmonary embolism (PE), cerebral thrombosis or MI.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Patients with hematuria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed Reda Abdelaziz, Professor</last_name>
    <phone>01003919165</phone>
    <email>mohamed.hassan19@med.au.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Mokhtar Fathy, Lecturer</last_name>
    <phone>01063317380</phone>
    <email>ahmedmokhtar_80@aun.edu.eg</email>
  </overall_contact_backup>
  <reference>
    <citation>van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009 Sep;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028. Epub 2009 Jun 26. Review.</citation>
    <PMID>19576682</PMID>
  </reference>
  <reference>
    <citation>Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20. Review.</citation>
    <PMID>19054893</PMID>
  </reference>
  <reference>
    <citation>Thompson E. Urological oncology in Europe. Research highlights from the XVIIth congress of the European Association of Urology, Birmingham, UK, February 23-26, 2002. Drugs Today (Barc). 2002 Apr;38(4):221-34.</citation>
    <PMID>12532191</PMID>
  </reference>
  <reference>
    <citation>Meyer JP, Blick C, Arumainayagam N, Hurley K, Gillatt D, Persad R, Fawcett D. A three-centre experience of orthotopic neobladder reconstruction after radical cystectomy: revisiting the initial experience, and results in 104 patients. BJU Int. 2009 Mar;103(5):680-3. doi: 10.1111/j.1464-410X.2008.08204.x. Epub 2008 Dec 2.</citation>
    <PMID>19076133</PMID>
  </reference>
  <reference>
    <citation>Cookson MS, Chang SS, Wells N, Parekh DJ, Smith JA Jr. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol. 2003 Jan;169(1):101-4.</citation>
    <PMID>12478113</PMID>
  </reference>
  <reference>
    <citation>Lawrentschuk N, Colombo R, Hakenberg OW, Lerner SP, Månsson W, Sagalowsky A, Wirth MP. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol. 2010 Jun;57(6):983-1001. doi: 10.1016/j.eururo.2010.02.024. Epub 2010 Feb 26. Review.</citation>
    <PMID>20227172</PMID>
  </reference>
  <reference>
    <citation>Lowrance WT, Rumohr JA, Chang SS, Clark PE, Smith JA Jr, Cookson MS. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol. 2008 Apr;179(4):1313-8; discussion 1318. doi: 10.1016/j.juro.2007.11.084. Epub 2008 Mar 4.</citation>
    <PMID>18289578</PMID>
  </reference>
  <reference>
    <citation>Chang SS, Smith JA Jr, Wells N, Peterson M, Kovach B, Cookson MS. Estimated blood loss and transfusion requirements of radical cystectomy. J Urol. 2001 Dec;166(6):2151-4.</citation>
    <PMID>11696725</PMID>
  </reference>
  <reference>
    <citation>Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW, Donat SM. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009 Jan;55(1):164-74. doi: 10.1016/j.eururo.2008.07.031. Epub 2008 Jul 18.</citation>
    <PMID>18675501</PMID>
  </reference>
  <reference>
    <citation>Novara G, De Marco V, Aragona M, Boscolo-Berto R, Cavalleri S, Artibani W, Ficarra V. Complications and mortality after radical cystectomy for bladder transitional cell cancer. J Urol. 2009 Sep;182(3):914-21. doi: 10.1016/j.juro.2009.05.032. Epub 2009 Jul 17.</citation>
    <PMID>19616246</PMID>
  </reference>
  <reference>
    <citation>Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol. 2010 Sep;184(3):990-4; quiz 1235. doi: 10.1016/j.juro.2010.05.037.</citation>
    <PMID>20643429</PMID>
  </reference>
  <reference>
    <citation>Quek ML, Stein JP, Daneshmand S, Miranda G, Thangathurai D, Roffey P, Skinner EC, Lieskovsky G, Skinner DG. A critical analysis of perioperative mortality from radical cystectomy. J Urol. 2006 Mar;175(3 Pt 1):886-9; discussion 889-90.</citation>
    <PMID>16469572</PMID>
  </reference>
  <reference>
    <citation>Clément C, Rossi P, Aissi K, Barthelemy P, Guibert N, Auquier P, Ragni E, Rossi D, Frances Y, Bastide C. Incidence, risk profile and morphological pattern of lower extremity venous thromboembolism after urological cancer surgery. J Urol. 2011 Dec;186(6):2293-7. doi: 10.1016/j.juro.2011.07.074. Epub 2011 Oct 20.</citation>
    <PMID>22014814</PMID>
  </reference>
  <reference>
    <citation>Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol). 1980;14:41-7. Review.</citation>
    <PMID>7000846</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>August 30, 2020</last_update_submitted>
  <last_update_submitted_qc>August 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Dalia Mohamed Abbas</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

